AbCellera Biologics Inc. (NASDAQ:ABCL) is one of the 8 Best Healthcare AI Stocks to Buy According to Analysts. On April 22, 2026, JonesResearch highlighted AbCellera Biologics Inc. (NASDAQ:ABCL), noting that if its ABCL635 candidate demonstrates clean safety with no hepatic signals and achieves target engagement comparable to Veohah and Lynkuet, the therapy could be “very competitive.” The firm has reiterated its Buy rating and $11 price target on AbCellera Biologics Inc. (NASDAQ:ABCL) ahead of a Phase 1 ...